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Abstract
Background: The development of anaemia in feline leukaemia virus (FeLV)-infected cats is associated with the
emergence of a novel viral subgroup, FeLV-C. FeLV-C arises from the subgroup that is transmitted, FeLV-A, through
alterations in the amino acid sequence of the receptor binding domain (RBD) of the envelope glycoprotein that
result in a shift in the receptor usage and the cell tropism of the virus. The factors that influence the transition from
subgroup A to subgroup C remain unclear, one possibility is that a selective pressure in the host drives the
acquisition of mutations in the RBD, creating A/C intermediates with enhanced abilities to interact with the FeLV-C
receptor, FLVCR. In order to understand further the emergence of FeLV-C in the infected cat, we examined primary
isolates of FeLV-C for evidence of FeLV-A variants that bore mutations consistent with a gradual evolution from
FeLV-A to FeLV-C.
Results: Within each isolate of FeLV-C, we identified variants that were ostensibly subgroup A by nucleic acid
sequence comparisons, but which bore mutations in the RBD. One such mutation, N91D, was present in multiple
isolates and when engineered into a molecular clone of the prototypic FeLV-A (Glasgow-1), enhanced replication
was noted in feline cells. Expression of the N91D Env on murine leukaemia virus (MLV) pseudotypes enhanced viral
entry mediated by the FeLV-A receptor THTR1 while soluble FeLV-A Env bearing the N91D mutation bound more
efficiently to mouse or guinea pig cells bearing the FeLV-A and -C receptors. Long-term in vitro culture of variants
bearing the N91D substitution in the presence of anti-FeLV gp70 antibodies did not result in the emergence of
FeLV-C variants, suggesting that additional selective pressures in the infected cat may drive the subsequent
evolution from subgroup A to subgroup C.
Conclusions: Our data support a model in which variants of FeLV-A, bearing subtle differences in the RBD of Env,
may be predisposed towards enhanced replication in vivo and subsequent conversion to FeLV-C. The selection
pressures in vivo that drive the emergence of FeLV-C in a proportion of infected cats remain to be established.
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Background
Feline leukaemia virus (FeLV) is an important pathogen of
both domestic cats and endangered felid species alike [1,2].
There are three main subgroups of FeLV; FeLV-A, B and C;
however, there is evidence that only FeLV-A is transmitted
efficiently between hosts [1,3]. Although FeLV-B and C are
fully replication competent in vitro [4,5], replication in vivo
is thought to require the presence of FeLV-A; thus the A
subgroup is commonly referred to as a “helper” virus, being
required for transmission and dissemination of FeLV-B and
C within the host.
FeLV-A is often mistakenly termed the “low-
pathogenicity” variant [6] as approximately 60% of
exposed cats mount a competent immune response and
successfully clear infection following a transient viraemia
[7,8]. However, the pathogenicity of FeLV-A is well docu-
mented and in chronically infected cats a range of clin-
ical signs may develop, including immunosuppression,
lymphoma and anaemia [9-11]. The disease association
and clinical prognosis are influenced by both the geno-
type of the FeLV-A isolate and the presence of other sub-
groups which arise in vivo [12]. FeLV-B and -C arise
within the infected host through either recombination
with endogenous retroviral transcripts [13] or through
the gradual acquisition of mutations within the viral gen-
ome [14], respectively. These viral subgroups are there-
fore usually identified alongside a concurrent FeLV-A
infection [15-17].
FeLV-C is found in approximately 1-2% of chronically
infected cats, and its emergence is associated with the
development of pure red cell aplasia (PRCA) [9,16,18].
This non-regenerative anaemia is fatal within approxi-
mately 2–3 months of FeLV-C arising in the cat [4,19].
The development of FeLV-C from the initial infection
with a FeLV-A isolate is accompanied by an alteration in
the receptor usage of the virus, from the thiamine trans-
porter THTR1 utilised by FeLV-A [20] to the haem
transporter, FLVCR1 utilised by FeLV-C [21]. The bind-
ing of FeLV-C to FLVCR1 impairs the normal cellular
function of the protein, preventing haem transport in
erythroid cells and resulting in a depletion of erythrocyte
precursors [22,23]. Although the widespread cellular dis-
tribution of both feTHTR1 and feFLVCR1 in the cat
means that FeLV-A and -C are able to infect multiple
lineages of haematopoietic cells (lymphoid, erythroid and
myeloid), the pathogenic potential of subgroup C viruses
appears to be conferred by the ability to interfere with
the function of FLVCR1 on erythroid progenitor cells, ra-
ther than the widespread infection of diverse cell types
[24].
The development of either FeLV-B or -C, and the ac-
companying diseases associated with these subgroups, is
due to alterations within the surface unit (SU, or gp70)
domain of the envelope glycoprotein gene (env) [13,14].
These mutations affect the amino acid sequence of the
receptor-binding domain (RBD) within SU, the region of
Env that determines the cognate receptor used for cellu-
lar entry. Accordingly, mutations within this region of
Env alter the cellular tropism of the virus and both
FeLV-B and -C possess expanded in vitro host ranges
[1,25-27]. Previous studies demonstrated that a 241
amino acid region within the Env of prototype FeLV-C
(Sarma) conferred the ability to induce PRCA in experi-
mental infections [28]. Subsequently, the primary deter-
minant of this phenotype was mapped more precisely to
a string of 92 amino acids within the RBD of isolates of
FeLV-C cloned biologically [14,29]. It was noted that
there was limited conservation between the sequence of
individual isolates of FeLV-C, supporting the assertion
that there is minimal inter-host transmission of FeLV-C
and that each isolate arises de novo within a unique host.
Protein signatures or structures that are conserved be-
tween all FeLV-C isolates have yet to be identified, and
the critical residues that are essential and sufficient to
confer FLVCR binding upon Env have not been
elucidated.
It has been assumed that the acquisition of the Env
mutations that define the C subgroup would lead to the
emergence of two distinct viral populations with non-
overlapping receptor tropisms within the host, resulting
in the FeLV-A/FeLV-C co-infections observed in clinical
cases. However, recent studies have suggested that the
evolution of FeLV-C in vivo may be a gradual process,
with viruses displaying intermediate phentoypes and re-
ceptor usages co-existing within the infected host. In-
deed, virus isolates have since been identified that utilise
both THTR1 and multiple FLVCR1 paralogues [30]. Pre-
sumably, these FeLV-A/C dual-tropic viruses would
eventually give rise to an isolate of FeLV-C that would
utilise FLVCR1 solely.
The initial aims of this study were to investigate how
specific mutations within FeLV-A Env influence its abil-
ity to evolve into dual-tropic variants and to identify the
mutations present in dual-tropic FeLV-A/C viruses that
confer an expanded receptor usage. This would allow an
insight into the sequence of molecular events leading to
the development of a highly pathogenic retroviral vari-
ant. We utilised primary field isolates of FeLV which had
been confirmed previously by receptor interference stud-
ies to contain both subgroups A and C. Comparisons be-
tween the env genes of these subgroup A strains with
those of prototypic strains of FeLV would allow identifi-
cation of mutations which may contribute to an initial
interaction with FLVCR1. Their presence would there-
fore enhance the possibility of FeLV-C development oc-
curring following genetic drift during subsequent cycles
of replication. Here, we examine the subgroup A compo-
nents of primary anaemogenic strains of FeLV and
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identify amino acid residues that result in an enhanced
receptor usage and replicative capacity.
Results
Anaemogenic strains of FeLV are composed of
heterogeneous viral populations
The nucleic acid sequences of env genes from seven pri-
mary isolates of anaemogenic strains of FeLV were deter-
mined. Each isolate had been confirmed previously by
classical assays for receptor interference as consisting of
a mixture of subgroups A and C. Consistent with their
designations by interference, multiple unique env clones
were obtained from each isolate, confirming the hetero-
geneity of the viral populations within these primary iso-
lates. The majority of variation between Envs was
located within the region encoding the RBD (Figure 1).
By comparing the amino acid sequences of the novel var-
iants with the prototypic FeLV-A (Glasgow-1) [13] and
FeLV-C (Sarma) [4] strains, each Env was tentatively
identified as either the subgroup A or subgroup C com-
ponent of the isolate. Our criteria for classification as a
likely subgroup C Env were the presence of substantial
amino acid substitutions and/or length polymorphisms
in the “Vr1” region [14] of the RBD. Viral variants that
appeared genetically to be of the FeLV–B subgroup
(present in isolates FY981 and FZ215) due to character-
istic recombination events with large stretches of en-
dogenous FeLV sequences were not included in
subsequent analyses.
The sequences of the FeLV-A components were highly
conserved between isolates, despite the lengthy interim
between their isolation. It is widely assumed that all ret-
roviruses acquire significant levels of variation over time
due to the error prone enzymatic activity of reverse tran-
scriptase, the actions of cellular antiviral factors such as
APOBECs, and the selective pressure from the host im-
mune response. However, while this is indeed the case
for the human immunodeficiency virus (HIV), and to
a lesser extent the feline immunodeficiency virus
(FIV), most isolates of FeLV-A are remarkably similar
[4]. In comparison, FeLV-C is thought to be poorly
transmissible, and each isolate arises independently
within the infected cat. This is reflected by the high
degree of divergence we observed in the RBD region
of Env between isolates. Despite this heterogeneity,
no mutations were identified that were conserved
across all the FeLV-C env sequences and an essential
Env determinant of the FeLV-C phenotype remains
to be identified.
Within the A/C mixtures, we observed Envs that were
ostensibly subgroup A by sequence alignment and yet
bore point mutations from the reference strain (FeLV-A
(Glasgow-1)). It can be assumed that the FeLV-A Envs
we identified were the parental viruses of the FeLV-C
isolates within their respective hosts, therefore we postu-
lated that these mutations may have affected the receptor
utilisation of the FeLV-A Env, increasing the likelihood
of FeLV-C developing. Within the FA27 isolate, variants
Figure 1 Sequence alignment of receptor binding domains from the envs of anaemogenic strains of FeLV. FEA cells were infected with
primary isolates of FeLV from cats with anaemia. Env genes were amplified from total cellular DNA, and the nucleic acid sequences of multiple
clones were determined. Sequences in blue were putatively assigned to subgroup A while sequences in red were assigned to subgroup C. Dots
indicate conservation with the A (Glasgow-1) sequence. Dashes are included to maintain alignment conservation in the presence of deletion or
insertions. Residues 83 and 91 in the N terminal region are highlighted.
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were identified with an aspartate to asparagine substitu-
tion D83N, a residue that varied in two of the novel
FeLV-Cs. This non-conservative mutation (D83N) was
documented previously in the FY981 virus [30], a variant
that is able to utilise FLVCR1, FLVCR2 and THTR1 [30].
Similarly, an asparagine to aspartate substitution (N91D)
was present in three of the novel FeLV-As (L3128F,
FZ215 and FA27), ablating a potential site for N-linked
glycosylation and aligning with a region of FeLV-C Envs
that is critical to the determination of the subgroup C
phenotype [4,14]). Asparagine-91 of FeLV-A (Glasgow-1)
is replaced with a Serine (S91) in both FeLV-A (3281)
and FeLV-A (61E) [6]. In contrast, FeLV-A (Rickard),
which has been shown to give rise to FeLV-C in vivo
[31,32], contains an aspartate residue (D91). D91 is also
found in FeLV-C(Sarma) [4] and FeLV-A(945) [33]. As
the D83N and N91D substitutions were localised to the
primary determinant of FeLV-C receptor usage, we
investigated a possible role for these residues in the evo-
lution of FeLV-C from FeLV-A.
D83N and N91D bearing mutants of FeLV-A (Glasgow-1)
are replication-competent
The wildtype genotype of FeLV-A (Glasgow-1) Env is
D83:N91 (DN). Using site-directed mutagenesis, we
developed three mutants of the FeLV-A(Glasgow-1) mo-
lecular clone, designated FeLV-A (Glasgow-1) D83:D91
(DD), N83:D91 (ND) and N83:N91 (NN). HEK293T cells
were then transfected with the functional molecular
clones and a chronic FeLV infection of each mutant virus
was established. Active infection was confirmed after two
weeks in culture by immunoblotting for both viral capsid
protein p27 and Env protein gp70 (Figure 2A). During
the preparation of virus stocks of the four variants, it
was noted that the DD mutant appeared to grow more
efficiently in HEK293T cells. In order to measure the ap-
proximate titre of the four virus preparations, serial dilu-
tions of the HEK293T-derived viruses were prepared,
plated onto QN10 (S + L-) cells, and the number of foci
per μl was quantified. This S + L- assay is used widely to
confirm the presence of an infectious feline gammaretro-
virus [34] and indicated that despite transfection of
matched inputs of the four molecular clones into
HEK293T cells, the four viruses displayed differences in
infectious titre; DD achieved a significantly higher titre
than the reference A (Glasgow-1) while ND and NN
achieved lower titres (Figure 2B). These observations
suggested that the combination of residues D83 and D91
conferred an enhanced replicative capacity upon FeLV-A.
D83:D91 in Env enhances viral entry mediated by THTR1
and its homologues
As QN10 assays were designed to detect infectious virus
rather than to quantify viral entry, the Glasgow-1 (A),
DD, ND and NN envs were sub-cloned into a mamma-
lian cell expression vector in order to produce MLV
(FeLV) lacZ pseudotypes (murine leukaemia virus virions
bearing the FeLV Envs and carrying a lacZ marker gene),
thus facilitating quantification of viral titre based solely
on viral entry. Following infection of HEK293T cells with
matched inputs of the MLV(FeLV) lacZ pseudotypes
(Figure 3A), DD Env-bearing pseudotypes yielded a
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Figure 2 The DD mutant of FeLV-A (Glasgow-1) displays a higher infectious titre. (A) Three mutants of the FeLV-A (Glasgow-1) molecular
clone, possessing mutations at amino acids 83 and(or) 91, were transfected into HEK293T cells. While FeLV-A (Glasgow-1) (A) has the phenotype
D83:N91, the mutants DD, ND and NN were D83:D91, N83:D91 and N83:N91 respectively. Viral supernatant was harvested 72 hours post-
transfection, filtered and ultracentrifuged, separated by SDS-PAGE, immunoblotted and probed with either anti-gp70 (SU) or anti-p27 (CA). (B)
FeLV-A (Glasgow-1) (A) or the DD, ND and NN mutants were transfected into 293 T cells and the supernatant was recovered. Serial dilutions of
each supernatant were prepared and plated onto QN10 S+ L- cells. 72 hours post-infection, foci were scored manually, values represent the mean
+/− SEM of two independent experiments.
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higher titre than those bearing the parent Glasgow-1 Env
(Figure 3B). In contrast, ND Env-bearing pseudotypes
achieved a lower titre than Glasgow-1 Env-bearing pseu-
dotypes. As the MLV(FeLV) lacZ pseudotypes undergo a
single cycle of infection, the data suggest that the DD
mutation enhanced replication at the stage of viral entry.
HEK293T cells are susceptible to all subgroups of FeLV
and presumably express all the cognate receptors, al-
though this has never been confirmed directly. Hence,
although the DD Env appeared to confer enhanced viral
entry, this assay did not allow identification of the recep-
tor(s) being utilised by the virus. Therefore, we repeated
the lacZ pseudotype assay using Mus dunni tail fibroblast
(MDTF) cells engineered to express stably a range of
FeLV receptors. Cells were infected with matched inputs
(RT activity) of MLV(FeLV) lacZ pseudotypes, and the
efficiency of infection was quantified. The results indi-
cated that pseudotypes bearing the DD Env displayed a
significant increase in the usage of all three THTR1
orthologues in comparison with the wild type FeLV-A
(Glasgow-1) Env (Figure 4). In contrast, C (Sarma) Env-
bearing pseudotypes displayed a marked preference for
hFLVCR1-expressing MDTF cells.
Enhanced binding of FeLV D83:D91 SU viral receptors
In vitro studies with MLV(FeLV) pseudotypes had sug-
gested that the combination of D83 and D91 in Env con-
ferred enhanced viral entry. We asked whether this effect
was mediated by increased binding to the viral receptor
(s), THTR1 (FeLV-A receptor), FLVCR1 (FeLV-C recep-
tor) and Pit-1 (FeLV-B receptor). Recombinant SU pro-
teins were expressed transiently in HEK293T cells as C-
terminal fusions with human IgG-Fc. Immunoblot ana-
lysis with anti-gp70 MAb and anti-human IgG Fc con-
firmed the antigenicity and yield of the SU-Fc proteins
respectively, although we were not able to ascertain
whether N91 constituted a potential site for N-linked
glycosylation (Figure 5). SU-Fc binding to receptor-
expressing MDTF (murine) or 104 C1 (guinea pig) cells
was then assessed by flow cytometry using matched inputs
of SU-Fc protein (informed by immunoblotting of the re-
combinant SU-Fc proteins with anti-IgG-Fc, see Figure 5)
from FeLV-A Glasgow-1 (A), FeLV-B Gardner-Arnstein
(B) and FeLV-C Sarma (C) or the FeLV-A Glasgow-1
mutants D83:D91 (DD), N83:D91 (ND) and N83:N91
(NN). The subgroup A-derived A, DD, ND and NN SU-Fc
proteins bound to MDTF or 104 C1-expressed THTR1s, B
SU-Fc bound to huPit1 expressing MDTF cells (we were
unable to derived huPIT1-expressing 104 C1 cells) while C
SU-Fc bound most efficiently to human FLVCR1-expres-
sing MDTF or 104 C1 cells (Figure 6), confirming the spe-
cificity of the interactions. Each of the Fc-SU fusion
proteins displayed a degree of background binding to the
control MDTF and 104 C1 cells. Given the widespread ex-
pression of the major facilitator superfamily of cell surface
molecules, a degree of background binding should be
expected. Indeed MDTF cells are known to express both a
murine THTR1 homologue and an unidentified accessory
molecule that is required for FeLV infection [35]. It was
notable, however, that in spite of ensuring that equivalent
amounts of each of the Fc-SUs were used in the binding
studies, the DD mutant bound more efficiently to both
control and THTR1-expressing cells. Each of the subgroup
A-derived Fc-SUs bound most efficiently to feline, less so
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Figure 3 The DD Env supports more efficient infection of HEK293T cells. (A) MLV(FeLV) lacZ pseudotypes were prepared from HEK293T cells.
Samples of each pseudotype preparation were pelleted, separated by SDS-PAGE, immunoblotted and probed with either anti-FeLV gp70 or anti-
SFFV Gag. (B) Matched inputs (RT activity) of MLV(FeLV) lacZ pseudotypes bearing the Glasgow-1 (A), DD, ND or NN Envs, were plated onto
HEK293T cells. 72 hours post-infection, the cells were stained for expression of lacZ and counted manually. Values are presented as infectious units
per μl (I.U./ μl ), mean +/− SE of three independent experiments. The increase in titre noted for the DD mutant and the decrease in titre of the
ND mutant (asterisks) are statistically significant in comparison with A (Glasgow-1) (unpaired T test, p< 0.05).
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to human THTR1 and weaker still to porcine THTR1,
consistent with the cat being the natural host species for
FeLV. Of the four FeLV-A SU-Fcs, the DD mutant
appeared to display higher binding than the A, NN and
ND SU-Fcs to each of the THTRs, suggesting that the DD
combination may enhance the Env-receptor interaction,
implicating a molecular basis for the enhanced replication
(Figure 2) and viral entry (Figures 3 and 4). These findings
were mirrored using independently generated cell lines
derived from 104 C1 cells. The binding studies with the
104 C1 cells suggested that the NN and ND SU-Fc pro-
teins bound less efficiently to 104 C1-expressed THTR1s
than the parental A SU-Fc, suggesting that while muta-
tions such as DD may enhance SU-Fc binding, the con-
verse may be true of NN and ND mutations. As binding of
the NN and ND Fc-SUs to THTR1s expressed on MDTF
cells was indistinguishable to that of the control A Fc-SU,
the data suggest that the cellular milieu in which the
receptors are expressed may influence the functionality of
the molecule as a viral receptor. Significant weak binding
of all SU-Fcs was noted to control MDTF and 104 C1 cells
although it was notable that the A and B SU-Fcs had
higher background binding than the C SU-Fc protein. It
was notable that while the DD SU-Fc bound with a higher
efficiency than the other A SU-Fcs to the control MDTF
cells, it bound with a similar efficiency to huFLVCR2-
expressing cells. As the A, NN, ND and DD SU-Fcs bound
to huFLVCR2-expressing cells with similar efficiencies,
these data strongly suggest that the enhanced binding of
the DD SU-Fc to diverse receptors is a specific property of
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Figure 4 The DD Env confers enhanced utilisation of THTR1 homologues. MLV (FeLV) lacZ pseudotypes bearing the A (Glasgow-1), C
(Sarma), DD, ND or NN Envs were plated onto MDTF cells expressing the feline (fe), human (hu) or porcine (po) THTR1 homologues, human
FLVCR1 or human FLVCR2. 72 hours post-infection, cells were stained for expression of lacZ and counted manually. Values represent the mean
+/− SEM of three independent experiments. The increase in titre associated with the DD mutation upon feline, human or porcine THTR1 is
statistically significant in comparison with A (Glasgow-1) (unpaired T test, p< 0.05).
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Figure 5 Expression of soluble Fc-tagged FeLV-SUs. HEK293T
cells were transfected with the pTORSTEN vector into which the SU
domains of the Glasgow-1 (A), Gardner-Arnstein (B) and Sarma (C), or
the Glasgow-1 mutants DD, ND and NN had been cloned. Matched
volumes of supernatant were separated by SDS-PAGE, transferred to
nitrocellulose and immunoblotted for both gp70 (4-15% gradient
gel, upper) and the human IgG Fc tag (8% linear gel, lower).
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the DD SU receptor binding domain and not a reflection
of variations in the amount of viable SU-Fc in the prepar-
ation. Given that the development of FeLV-associated
erythroid hypoplasia is marked by a shift in receptor usage
from THTR1 to FLVCR, the enhanced binding afforded by
the DD mutation may be highly significant in the spread
of such variants into compartments expressing the FLVCR
receptor; this likely represents the first step towards the
biological selection of subgroup C viruses.
Selective pressures driving the emergence of FeLV-C
If, as we predict, the acquisition of substitutions such as
N83D and N91D renders the virus more likely to evolve
from subgroup A to subgroup C, we may be able to ob-
serve this process of evolution in vitro by attempting to re-
create a similar milieu to that observed in vivo.
Unfortunately, the site of viral replication and evolution
in vivo remains unclear, and therefore we can only surmise
that it is a site in which both the A and C receptors are
expressed. Moreover, additional selective pressures may be
placed upon the evolution of the viral Env protein in vivo
from the adaptive (acquired) immune response of the host.
In order to investigate whether the humoral immune re-
sponse played a role in the evolution of FeLV-C, sera from
FeLV-infected cats were pooled and screened for reactivity
with gp70. During recovery from infection, cats mount a
neutralising response that targets gp70. Accordingly, by
pooling sera from recovered cats, we generated a cat poly-
clonal serum that reacted with gp70 on immunoblot
(Figure 7A) and which neutralised infection with FeLV
(Figure 7B). When the relative sensitivities of FeLV-A
Glasgow-1 and the DD, ND or NN mutants to neutralisa-
tion by either the pooled cat serum or a monoclonal anti-
body targeting gp70 (Figure 7C) were compared, no
significant differences were detected, suggesting that the
substitutions in amino acids 83 and 91 did not confer
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Figure 6 The DD mutation confers enhanced binding of Fc-SU to multiple receptors. Matched volumes of supernatant containing the Fc-
SU fusion proteins from Glasgow-1 (A), Gardner-Arnstein (B), Sarma (C), or the mutants DD, ND and NN, were added to either MDTF or 104 C1
cells expressing feline, human or porcine THTR1, human FLVCR1 & 2, human Pit1 (MDTF only), or vector only (CON). Fc-SU binding was detected
by flow cytometry with PE-conjugated anti-human IgG-Fc. Each histogram represents 10,000 events collected in LIST mode and are representative
of two independent analyses. Ordinate displays number of events while abscissa displays fluorescence intensity.
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resistance to either of these neutralising antibodies. As it is
likely that, in individual cats, the response to gp70 may be
epitope-specific and that the specificity of the response will
vary between cats, we cannot discount the possibility that
N83D or N91D containing variants may have either a
heightened or reduced sensitivity to neutralisation in vivo.
Next, we asked whether culturing each of the viruses in
the presence of sub-optimal neutralising concentrations of
antibody would promote the emergence of variants with
distinct receptor usages. FEA cells were infected with ei-
ther A (Glasgow-1) or the DD, ND and NN mutants
(MOI=0.01), and a productive infection established. Anti-
gp70 MAb or pooled FeLV-positive cat serum was added
to the culture medium after the first subculture (72 hours
post-infection). Ten days post-infection, the culture super-
natants were harvested, concentrated 100-fold by
ultracentrifugation, and screened by immunoblot for the
presence of viral p27 CA protein. While p27 was detected
in the concentrated culture supernatant from cells infected
with virus in the absence of antibody at both 10 and
28 days post-infection, both the polyclonal cat serum and,
more markedly, the mouse MAb, suppressed virus produc-
tion at 10 days post infection (Figure 8). As p27 produc-
tion was detected in all cultures by 28 days post-infection,
the data confirmed that we were using a sub-optimal neu-
tralising antibody concentration and that the culture sys-
tem was biased towards the emergence of neutralisation
escape mutants. The cultures were maintained for fifty
days in the presence of antibody with routine sub-culture,
after which the culture supernatants were harvested from
all cultures, concentrated by ultracentrifugation and viral
RNA was isolated. Env genes were amplified, cloned and
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Figure 8 Replication of FeLV in the presence of sub-neutralising concentrations of anti-FeLV antibodies. FEA cells were infected with FeLV
A(Glasgow-1) (A) or the DD, ND and NN mutants in the presence of sub-optimal neutralising concentrations of either pooled serum from FeLV-
positive cats or anti-gp70 MAb. Supernatant was harvested from infected cultures at 10 and 28 days post-infection, concentrated by
ultracentrifugation, viral pellets were then separated by SDS-PAGE, transferred to nitrocellulose and stained for capsid protein (p27).
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their nucleic acid sequences determined. A total of 62 env
sequences were determined from the 12 cultures (~5
sequences per culture) and were compared with the inoc-
ula used for infection.
A total of 59 mutations, 42 of which were non-
synonymous,were identified (Figure 9). With rare excep-
tions, each mutation was identified in a single clone. When
comparing the mutations which arose to those described
previously or those observed in our original primary iso-
lates (Figure 1), we observed no evidence for the selective
expansion of variants with FeLV-C-like sequences. The
level of variation varied widely between viruses and while
nine non-synonymous substitutions were detected in var-
iants amplified from the culture infected with the ND mu-
tant in the presence of anti-gp70 monoclonal antibody
(D30G, T49A, R263K, D305G, T336A, L476P, R482G,
M591T, L608P), no substitutions were detected in the cul-
ture infected with the NN mutant in the presence of anti-
FeLV polyclonal antibody (Figure 9). Mutations were dis-
persed across both SU (gp70) and TM (p15E) and were
not focussed to variable regions A and B (VRA and VRB)
or the proline rich region (PRR). The data indicate that
under the culture conditions utilised for this study, the
four variants had equal propensities to acquire mutations
in vitro and that the combinations of DN, DD, ND or NN
did not alter significantly the likelihood of the Env ac-
quiring non-synonymous mutations.
Discussion
The amino acid sequence of the receptor binding domain
(RBD) of the A subgroup of FeLV varies little between iso-
lates, constraining the virus to usage of the thiamine trans-
porter THTR1 for infection. The switch in subgroup from
A to C in cats with pure red cell aplasia is marked by
amino acid alterations in the RBD that shift receptor usage
from THTR1 to the haem transporter FLVCR1. While all
anaemogenic strains of FeLV bear such substitutions, little
is known about the genesis of the A to C switch. To date,
each isolate of FeLV-C studied has displayed a unique
RBD sequence, suggesting that recombination with en-
dogenous env sequences is an unlikely source of the
mutated RBD. In contrast, the emergence of subgroup B
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Figure 9 Acquisition of non-synonymous mutations in the envs of FeLV-A mutants following long-term culture. FEA cultures were
infected with FeLV-A (Glasgow-1), or the DD, ND and NN mutants in the presence of pooled feline sera from FeLV-positive cats, anti-gp70 MAbs,
or with no antibody (control). 50 days post-infection, env sequences were amplified from purified viral RNA, and their nucleic acid sequence were
determined.
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viruses is associated with recombination between exogen-
ous and endogenous FeLV env sequences [13,36,37]. A
more likely mechanism for the derivation of subgroup C
viruses would be the acquisition of mutations or deletions
in vivo in response to a selective pressure from the host,
either through pressure to escape the adaptive immune re-
sponse or through receptor availability in the tissue in
which the virus replicates. Such a mechanism predicts the
presence of variants with an intermediate tropism; sub-
group A viruses with point mutations in the RBD that con-
fer an enhanced or expanded receptor usage. Previous
studies identified a subgroup C virus, FY981 that had
retained the ability to utilise the subgroup A receptor
THTR1 for infection [30], confirming that there are indeed
“dual-tropic” or “poly-tropic” viruses amongst primary iso-
lates of anaemogenic strains of virus. FY981 is actually a
poly-tropic virus as it is able to utilise a third receptor
(FLVCR2) in addition to THTR1 and FLVCR1 [30]. Here,
we demonstrated that subtle variations in the RBD of sub-
group A viruses may have significant effects on the way
the viruses interact with their receptors, potentially predis-
posing the viruses to in vivo mutagenesis. Accordingly, the
presence of the combination of D83 and D91 in the back-
ground of A (Glasgow-1) was sufficient to enhance recep-
tor binding, viral entry and viral replication. Residue D91
is particularly intriguing as it is present in the well-charac-
terised Rickard strain of FeLV. In two separate studies
examining recombination in FeLV infection, it was noted
that inoculation of cats with a molecular clone (pFRA) of
the Rickard strain of FeLV resulted in 1 of 3 [31] and 1 of
5 [32] cats developing an FeLV-C associated anaemia. As
FeLV-C is thought to arise in <1% of infected cats, the
high incidence of FeLV-C emergence following inoculation
with FRA (33% and 20% respectively) may suggest an
enhanced propensity for the development of FeLV-C.
Mechanistically, a scenario can be envisaged whereby
some subgroup A viruses may be inherently more patho-
genic than others due to an enhanced ability to infect and
spread in the infected host, a feature determined largely by
the affinity of the Env for the viral receptor. Indeed, such a
virus (FeLV-945) has been described and shown to have a
higher binding affinity for its receptor [38]. Mapping the
determinants of the enhanced binding of the FeLV-945 SU
to feline cells suggested that the major determinant of the
enhanced binding of the 945 SU resided in variable region
B (VRB) of gp70. FeLV-945 is a D83:D91 virus, similar to
the DD mutant we examined in this study; however, insert-
ing the VRA of 945 in the background of FeLV-61E (an SU
that binds with a lower affinity to its receptor) did not con-
fer an enhanced binding upon the 61E SU, suggesting that
multiple determinants in gp70 may contribute to the re-
ceptor binding affinity. However, it should also be noted
that the 61E SU varies from the Glasgow-1 SU at a num-
ber of other residues across gp70; the context in which
D83:D91 is expressed may be critical to its effect on bind-
ing affinity. Moreover, in this study, we expressed SU fu-
sion proteins with a C-terminal IgG Fc-tag (dimeric) and
binding was assessed on both mouse and guinea-pig cells
expressing individual receptors, whereas the 945-SU pro-
teins [38] were expressed as C-terminal HA tagged pro-
teins (monomers) and binding assessed on the feline
lymphosarcoma cell line 3201, a cell line that produces a
soluble 35 kDa endogenous FeLV Env protein capable of
viral interference [39]. Such experimental differences may
modulate both the affinity and the specificity of the Env-
receptor interaction in the two systems. For example, it
has been shown that the context in which the receptor
THTR1 was expressed altered the efficiency of receptor
usage by FeLV [30] while soluble endogenous FeLV Env
produced from 3201 cells conferred infectivity on the
otherwise defective FeLV-T Env [40]. Irrespective of the
differences in the experimental systems, the enhanced
binding of the Glasgow-1 DD mutant SU-Fc to THTR1
was consistent with the enhanced entry and replication of
the virus, while the high affinity binding of the 945-SU was
consistent with enhanced binding of intact virus particles
from FeLV-945 to the same cells [38].
It is possible that both the affinity of the FeLV SU for
its cognate receptor and its ability to induce fusion once
bound combine to determine the eventual route of viral
entry. Our data may predict that during FeLV-C evolu-
tion, additional mutations accumulate during long-term
viral replication and that these mutations decrease SU af-
finity for THTR1 whilst increasing the relative affinity
for the FLVCR1 homologues. Such viral evolution would
eventually result in an Env capable of mediating fusion
and entry via FLVCR1, producing the FeLV-C phenotype
and associated PRCA symptoms. This theory is sup-
ported by the observation that FeLV-C (Sarma) displayed
a severely limited ability to bind to THTR1 despite pos-
sessing the D83:D91 motif. However this altered binding
affinity may be mediated by a range of mutations across
the SU, not comprising a single binding motif, explaining
why individual FeLV-C Env proteins are functionally but
not genetically conserved. It is possible that the overall
final Env conformation, rather than specific individual
residues, permits FLVCR1-mediated membrane fusion
and cellular entry. The deletions which we observed in
multiple FeLV-C env clones from our primary isolates
may be essential for decreasing the affinity of the
THTR1-SU interaction and allowing FLVCR1-mediated
entry. This deletion may represent the final mutation in
the progression from FeLV-A to -C. The mechanism(s)
underlying the deletion of residues within the RBD-
encoding region of env remain to be ascertained; how-
ever, a scenario could be envisaged wherein the RNA
structure within some regions may be less stable and in-
herently more likely to break and reform.
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Having established that subtle variations in the VRA of
FeLV-A could have a significant impact upon the bio-
logical properties of subgroup A FeLV Glasgow-1, we
asked whether we could mimic the in vivo selective pres-
sure exerted upon FeLV by the humoral immune system.
By culturing virus in the presence of sub-optimal concen-
trations of either monoclonal anti-gp70 antibody or pooled
serum from FeLV-infected cats, we demonstrated the ac-
quisition of non-synonymous mutations with time in cul-
ture, although we were not able to demonstrate a shift
from subgroup A (THTR1-using) to subgroup C
(FLVCR1-using). Subgroup C viruses emerge in an esti-
mated 1% of anaemic cats, suggesting that a relatively rare
set of circumstances combines to drive their evolution. It
is possible that the epitope specificity of the antibody re-
sponse elicited following infection may prove critical in
determining the composition of variants that evolve, and
so serum from cats from which FeLV-C had been isolated
rather than a diverse pool of FeLV-infected cat sera would
be required to mimic this response in vitro. While our
working hypothesis is that the humoral immune response
influences the likelihood of FeLV-C emerging in infected
cats, other factors may have a significant impact upon viral
evolution; for example VRA may constitute a T cell epitope
in some cats and pressure to escape a cellular immune re-
sponse may play a role in driving variation in VRA. Alter-
natively, variation amongst cats in both the levels of
receptor expression and the cell types upon which the
receptors are expressed may determine sites of viral repli-
cation. A scenario could be envisaged whereby co-expres-
sion of both THTR1 and FLVCR in the same cell may
permit the emergence of variants with dual tropisms and
ultimately a specific tropism for FLVCR1-expressing cells.
A detailed analysis of the mutations that were identi-
fied allowed several inferences to be made. Firstly, the
rate of mutation appeared consistent across all cultures,
indicating viral genetic drift occurred at similar rates re-
gardless of the presence or absence of VNAs. Addition-
ally, few mutations were identified more than once,
indicating a single FeLV genome had not emerged as the
dominant viral species in any culture. However, the lim-
ited capacity of our env selection method (cloning as
opposed to deep-sequencing) must be taken into account
as it is possible that the amplification of more env
sequences, or the use of alternative techniques, may have
produced different results. Amplification and cloning of
env genes may not provide a sufficiently broad picture of
the genomes present in the culture. It remains possible
that dual-tropic virus strains, or those containing muta-
tions indicative of a FeLV-C phenotype, were present in
some cultures, but were not detected during our analysis.
The results presented herein therefore represent a “snap-
shot” of the viral genomes present at 50 days post-infec-
tion. We were unable to determine whether specific
viruses formed prominent subpopulations during the
course of infection, indicative of a species with a replica-
tive advantage expanding.
Apart from viral genetic drift, there are numerous al-
ternative mechanisms for the observed mutations; for ex-
ample, some mutations may have arisen at sites as a
result of structural biochemistry. There is evidence that
adenine-thymine tracts (consisting of four consecutive A
or T nucleotides) are associated with “bends” in the nas-
cent DNA strand, and are more likely to be mutated
through misincorporation [41]. As 13 of the 59 muta-
tions (~22%) observed in the long-term replication study
occurred in AT-rich tracts (nucleotide data not shown),
it is possible these are due to this phenomenon, rather
than either neutralisation escape or receptor tropism ex-
pansion as originally predicted. In addition, some muta-
tions may have arisen as the result of apolipoprotein B
mRNA-editing enzyme catalytic polypeptide (APOBEC)
activity. APOBECs mutate retroviral genomes by deami-
nating the cytosines within DNA, eventually causing an
accumulation of G to A mutations in the RNA genome.
However, there was minimal evidence of APOBEC activ-
ity in the env sequences analysed in this study; of the 59
mutations identified only 7 were G-to-A transitions.
Additionally, only 3 of these 7 were found within likely
targets for feline APOBECs (AGG or GGG motifs) [42].
This is in accordance with other reports that APOBECs
exhibit weak restriction of FeLV in natural infections
[42,43].
The inclusion of VNAs in our long-term replication
study was based upon the assumption that FeLV-C evo-
lution may be a result of the replicating virus escaping
antibody-mediated neutralisation. This hypothesis is not
without precedent as there are numerous instances of
retroviral antigenic variation and receptor usage altera-
tions being driven by pressure from the host immune re-
sponse. VNA play a role in the selection and expansion
of viral variants in both simple and complex retroviruses,
and this has been mimicked successfully in vitro in nu-
merous cases [44-46]. In the example of equine infec-
tious anaemia virus (EIAV), an in vitro model of viral
evolution found that 13 viral passages were required to
obtain an antibody-escape mutant. This phenotype was
conferred by only two altered epitopes in the SU domain
[45]. This is a similar timespan to that used in our study,
indicating it was sufficient to observe antibody-escape
mutants. Despite the lack of FeLV-C associated muta-
tions observed here, development of FeLV-C as a conse-
quence of antibody escape remains a plausible theory.
There are numerous variables in this process which
could not be replicated in our model, including the
broad range of antibodies produced in a competent im-
mune response. Before definitive conclusions can be
drawn about the role of VNAs in FeLV-C development,
Stewart et al. Retrovirology 2012, 9:48 Page 11 of 15
http://www.retrovirology.com/content/9/1/48
this experiment should be repeated using a more exten-
sive range of both polyclonal and monoclonal antibodies.
Conclusions
Primary isolates of FeLV-A and C consist of heterogeneous
viral populations, and the subgroup A components of
these isolates display a range of subtle mutations in Env.
In the context of FeLV-A Glasgow-1, the combination of
D83 and D91 in gp70 allowed increased binding to
THTR1 and enhanced both viral entry and replication.
Such properties may predispose viruses to evolution from
subgroup A to subgroup C by enhancing spread of the
virus into cellular compartments where ability to use
FLVCR is selected preferentially. These data provide a first
step towards elucidating why FeLV-C emerges infrequently
in infected animals and provide further evidence that des-
pite a high degree of genetic homogeneity, not all FeLV-As
are equal.
Methods
Cell Lines and plasmid constructs
Mus dunni tail fibroblast (MDTF) cells (ATCC Catalogue
CRL-2017) and guinea pig fibroblast (104 C1) cells were
maintained in low-glucose DMEM (Gibco), supplemented
with 10% foetal bovine serum, 100U/mL penicillin and
100 μg/mL streptomycin. Human embryo kidney
(HEK293T) cells [47], feline embryo A (FEA) cells [26]
and QN10 (S+L- feline embryonic fibroblastic AH927)
cells were maintained in high-glucose DMEM (Gibco)
supplemented with 10% foetal bovine serum, 100U/mL
penicillin and 100 μg/mL streptomycin. The pMFG plas-
mid [48], encoding β-galactosidase (lacZ) with a MLV-
packaging signal, was used to detect pseudotype entry and
retroviral integration through expression of the lacZ re-
porter gene. The pCMVi plasmid [49] encodes MLV gag-
pol and was used to produce MLV-packaged pseudotypes.
Retroviral expression vectors based upon the pFB-NEO
plasmid (Agilent Technologies) containing the complete
cDNA of various retroviral receptors with 5’ haemaglutin-
nin (HA) tags were kindly provided by Prof C. Tailor, Uni-
versity of Toronto [50,51]. The pVR1012 plasmid is a
eukaryotic expression vector modified from the pUC plas-
mid [52] containing a cytomegalovirus early promoter to
drive target gene expression. The pTORSTEN expression
vector drives expression of soluble proteins with an incor-
porated C-terminal human IgG1-Fc tag [53].
Molecular cloning of proviral env genes from primary
isolates
Feline embryonic fibroblast (FEA) cells were infected
with seven primary FeLV isolates from the United King-
dom, isolated from 1977 to 1994. The FEA cell line is
permissive to all three subgroups of FeLV and therefore
would not be expected to restrict the growth of any viral
variants. The seven isolates had been classified previously
by interference assays [17] and found to be FeLV-A/C
co-infections. Two isolates also contained FeLV-B (A/B/
C mixtures). Successful infection and viral release from
the FEA cells was confirmed by a enzyme-linked im-
munosorbent assay (ELISA) for the viral capsid protein
p27 (data not shown). Proviral env sequences were
amplifed from purified genomic DNA by using the poly-
merase chain reaction (PCR) using primers based upon
published exogenous strains of FeLV. The amplified envs
were cloned into the pCR2.1 vector (Invitrogen Life
Technologies Ltd., Paisley UK) and the nucleic acid se-
quence determined using the BigDye Terminator v1.1
Kit (Applied Biosystems, Paisley, U.K.) followed by ana-
lysis on using an ABI Prism 3130xl Genetic Analyser
(Applied Biosystems). Nucleic acid sequences and their
predicted amino acid translations were processed using
Accelrys Gene 2.5. Nucleic acid alignments were gener-
ated using ClustalW and MEGA5.
Stable transduction of MDTF and 104 C1 cells
VSV-G-enveloped pseudotypes encapsulating transcripts
of the pFB-NEO vector, encoding cDNAs of the desired
receptor, were produced by transient transfection of
HEK293T cells. Cells were transfected with Superfect Re-
agent (Qiagen, U.K.) according to the manufacturer’s
protocol. 72 hours post-transfection, pseudotypes were
harvested, passed through a 0.45 μm filter, and used to
infect 1x105 adherent cells. 72 hours post-infection the
stably-transduced cells were selected by G418 treatment
(800 μg/mL). Expression of the retroviral receptor was
confirmed using immunofluorescence directed against
the C-terminal HA tag.
Site-directed mutagenesis
The QuickChange Lighting Mutagenesis kit (Agilent
Technologies, U.K.) was utilised to mutate the D83 and
N91 residues of the FeLV-A(Glasgow-1) molecular clone.
The protocol was conducted according to manufacturer’s
instructions; however PCR products were precipitated
with ethanol/sodium acetate following Dpn1 treatment.
They were then resuspended in a small volume of water
prior to transformation into competent cells. The se-
quence of mutagenesis primers is available upon request.
Neutralising antibody preparations
Neutralising murine monoclonal antibody 46II F2 D10 F4
I3 against the FeLV gp70 was obtained from Prof. H. Lutz.
It is not known which epitope within gp70 the MAb tar-
geted. Serum samples from FeLV naturally-infected, recov-
ered cats were kindly donated by the Companion Animal
Diagnostic Unit, University of Glasgow. Their assays, being
virus isolation and capsid ELISAs, had confirmed the sera
were all FeLV virus-negative and antibody positive. Positive
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sera were pooled and used in virus neutralisation and
long-term viral replication assays.
Immunoblotting
Immunoblots were performed to detect expression of spe-
cific proteins in both feline sera and concentrated virus
preparations (prepared by centrifugation of cell-free virus
supernatant, at 30 000 rpm for one hour in a Beckman
Ultracentrifuge with a SW40 rotor). Samples were diluted
to the desired volume using bromophenol blue protein
loading buffer and heated to 90°C for five minutes prior to
electrophoresis. Electrophoresis was conducted in 4-12%
gradient precast polyacrylamide gels (Invitrogen) at 90 V
for two hours. Proteins were transferred to nitrocellulose
membranes using the iBlot transfer system (Invitrogen).
Membranes were blocked overnight using 2% skimmed
milk powder and 0.1% Tween-20. Primary antibodies
against the CA proteins (VPG19.1 anti-FeLV p27 or R187
anti-SFFV p30) were used at a dilution of 1:500, whereas
the anti-gp70 MAb was used at 1:104 in blocking buffer.
Biotinylated secondary antibodies from various species
were utilised (Vector Laboratories, U.K.) at a 1:1000 dilu-
tion in blocking buffer. An alkaline phosphatase-labelled
avidin complex was then bound to the membrane (ABC-
AmP kit, Vector Laboratories), before proteins were visua-
lised using a chromogenic alkaline phosphatase substrate.
QN10 focus-forming assays
QN10 (S + L-) cells were seeded into 6 well plates at 20%
confluency and allowed to adhere overnight prior to in-
fection. Infectious virus was produced by transient trans-
fection of HEK293T cells with molecular clones based
upon the FeLV-A (Glasgow-1) construct. Viral super-
natant was harvested and used to infect the cells for two
hours at 37°C. 72 hours post-infection, the numbers of
foci were manually counted and the viral titre (in FFU/
μL) was calculated.
LacZ staining
Pseudotypes containing the Env proteins of interest and
encapsulating transcripts of the pMFG plasmid were
used to infect both HEK293T and MDTF cells. 72 hours
post-infection, lacZ expression was measured by 5-
bromo-4-chloro-3-indolyl-β-d-galactoside (X-Gal) stain-
ing. Briefly, confluent monolayers of cells were washed
in PBS before being fixed with 0.5% glutaraldehyde for
30 minutes. Fixative solution was removed and cells re-
washed before the addition of staining solution (PBS
containing 0.02% X-Gal, 3 mM ferro-cyanide, 3 mM
ferri-cyanide, 1.3 mM MgCl2). Plates were stored at 4°C
overnight before the lacZ-expressing cells (indicated by a
blue appearance) were manually counted.
Cell-binding assays with soluble SU proteins
The pTORSTEN expression vector was used to express
soluble Fc-SU fusion proteins with an incorporated C-
terminal human IgG1-Fc tag [53]. The SU domains of all
Env proteins were subcloned into pTORSTEN, HEK293T
cells were then transiently transfected using polyethyleni-
mine (Polysciences Inc., U.K.) and the supernatant con-
taining the protein of interest was harvested 3 days post-
transfection and passed through a 0.45 μm filter. Expres-
sion of soluble proteins was confirmed by immunoblotting
using both anti-gp70 and anti-Fc. For cell-binding assays,
MDTF and 104 C1 cells were dispersed using 1 mM
EDTA before 50μL of protein-containing supernatant was
incubated with 105 cells for 30 minutes on ice. Cells were
washed with PBS containing 1% bovine serum albumin
and 0.1% sodium azide (PBS-BSA-Az). 0.5 μg of PE-la-
belled antibody specific for human IgG (eBiosciences, U.
K.) was then added to each reaction and incubated for a
further 30 minutes on ice. Cells were washed and resus-
pended in PBS-BSA-Az before before analysed on a Beck-
man Coulter Cytomics FC500 flow cytometer.
Env cloning from viral RNA
Viral supernatant from chronically infected FEA cultures
was harvested and passed through a 0.45 μm filter, prior to
ultracentrifugation at 30 000 rpm for one hour at 4°C.
Viral pellets were re-suspended overnight at 4°C in PBS.
Viral RNA was extracted using the QIAamp UltraSens
Viral kit (Qiagen) according to manufacturer’s instruc-
tions. Following elution with water the RNA was DNase-
treated to remove potential contaminating cellular gDNA
(Amplification-grade DNase, Invitrogen). DNase was inac-
tivated by EDTA-treatment and heating the sample to 65°
C for 15 minutes. First-strand cDNA synthesis using oligo-
dT primers was conducted with a commercial MLV RT
enzyme (Invitrogen) according to manufacturer’s instruc-
tions. Ribonuclease inhibitors (RNaseOUT, Invitrogen)
were included in all cDNA synthesis preparations. Oligo-
nucleotide primers for amplification of env sequences were
obtained from MWG Biotech (Ebersberg, Germany); pri-
mer sequences are available upon request. All PCRs were
conducted using a commercially available mastermix
(High Fidelity PCR Master, Roche, U.K.). Amplicons were
cloned into the pVR1012 vector and the inserted env genes
were sequenced using the BigDye Terminator v1.1 Cycle
Sequencing kit (Applied Biosystems, U.K.) according to
manufacturer’s instructions. Sequencing reaction products
were analysed using an ABI Prism 3130xl Genetic Analyser
(Applied Biosystems) and data analysed using the DNA
Dynamo (Blue Tractor Software Ltd, U.K.) and SeaView
software [54].
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